APA (7th ed.) Citation

Hajda, J., Leuchs, B., Angelova, A. L., Frehtman, V., Rommelaere, J., Mertens, M., . . . Ungerechts, G. (2021). Phase 2 trial of oncolytic H-1 parvovirus therapy shows safety and signs of immune system activation in patients with metastatic pancreatic ductal adenocarcinoma. Clinical cancer research, 27(20), . https://doi.org/10.1158/1078-0432.CCR-21-1020

Chicago Style (17th ed.) Citation

Hajda, Jacek, et al. "Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients with Metastatic Pancreatic Ductal Adenocarcinoma." Clinical Cancer Research 27, no. 20 (2021). https://doi.org/10.1158/1078-0432.CCR-21-1020.

MLA (9th ed.) Citation

Hajda, Jacek, et al. "Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients with Metastatic Pancreatic Ductal Adenocarcinoma." Clinical Cancer Research, vol. 27, no. 20, 2021, https://doi.org/10.1158/1078-0432.CCR-21-1020.